Dr. Reddy's RIVASTIGMINE Capsules Recall: Cross-contamination Risk
Dr. Reddy's recalls 1.5 mg Rivastigmine Tartrate Capsules due to cross-contamination with ranitidine. This may affect patients using the medication. Contact for details.
Lower-risk recall
Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
Contact the company
What happened, in plain English
Dr. Reddy's is recalling 1.5 mg Rivastigmine Tartrate Capsules because testing found ranitidine contamination. This could cause unintended medication interactions for patients using the drug. Read more at govinfonow.com/recall/41859-dr-reddy-s-rivastigmine-capsules-recall-cross-contamination-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41859-dr-reddy-s-rivastigmine-capsules-recall-cross-contamination-risk · Updated October 8, 2026 · FDA enforcement record: FDA #D-0649-2017
Cite this page
“Dr. Reddy's RIVASTIGMINE Capsules Recall: Cross-contamination Risk.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41859-dr-reddy-s-rivastigmine-capsules-recall-cross-contamination-risk. Based on FDA recall #D-0649-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0649-2017%22&limit=1).
Why it’s dangerous
The testing detected ranitidine, a medication used for ulcers, in the Rivastigmine capsules. This cross-contamination could lead to unintended medication interactions if the patient is taking ranitidine or has a sensitivity to it.
Who’s affected
Patients prescribed Rivastigmine Tartrate Capsules for conditions like Alzheimer's disease. Those with specific allergies to ranitidine may be at higher risk.
How to tell if you have this one
Check for the 1.5 mg Rivastigmine Tartrate Capsules, 60-count bottle, Rx Only, with NDC 55111-352-60. The lot number C607323 was manufactured in India and expires October 2018.
- Brand
Dr. Reddy's- Category
Drug
What to do — step by step
Check Your Medication
Look for the 1.5 mg Rivastigmine Tartrate Capsules, 60-count bottle, Rx Only, with NDC 55111-352-60 and lot number C607323.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “U.S. nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 10 months after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Dr. Reddy's recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0649-2017 (March 6, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0649-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.